Shares of China's CanSino Biologics rise as much as 15% on Wednesday afternoon. Cansino and Aerogen are teaming up to develop and market an inhaled version of CanSino's recombinant COVID-19 shot Convidecia, which is already approved in China as a one-and-done injectable. 康希諾生物日內走高,一度漲超15%,此前宣佈與Aerogen合作開發全球首款吸入式新冠疫苗。 $康希諾生物(06185.HK)$$康希諾(688185.SH)$
康希諾股票討論區
$科興生物(SVA.US)$ $復星醫藥(02196.HK)$ $復星醫葯(600196.SH)$ $康希諾(688185.SH)$ $康希諾生物(06185.HK)$ $沃森生物(300142.SZ)$ $智飛生物(300122.SZ)$
$康希諾生物(06185.HK)$ $康希諾(688185.SH)$
Cansino and Aerogen are teaming up to develop and market an inhaled version of CanSino's recombinant COVID-19 shot Convidecia, which is already approved in China as a one-and-done injectable.
康希諾生物日內走高,一度漲超15%,此前宣佈與Aerogen合作開發全球首款吸入式新冠疫苗。
$康希諾生物(06185.HK)$ $康希諾(688185.SH)$
$康希諾(688185.SH)$
$康希諾(688185.SH)$
暫無評論